Product Description
Guanfacine is in a class of medications called centrally acting alpha2A-adrenergic receptor agonists. Guanfacine treats high blood pressure by decreasing heart rate and relaxing the blood vessels so that blood can flow more easily through the body. Guanfacine extended-release tablets may treat ADHD by affecting the part of the brain that controls attention and impulsivity. (Sourced from: https://medlineplus.gov/druginfo/meds/a601059.html)
Mechanisms of Action: ADR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | India | Ireland | Japan | Latvia | Lithuania | Morocco | Netherlands | Norway | Pakistan | Peru | Poland | Portugal | Slovakia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Attention Deficit Disorder with Hyperactivity
Phase 2: Breast Cancer|Down Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HYP01 | P2 |
Recruiting |
Down Syndrome |
2025-11-01 |
12% |
2025-04-05 |
Primary Endpoints|Start Date|Treatments |
| 2016-000506-11 | P2 |
Active, not recruiting |
Breast Cancer |
2016-12-22 |
2025-05-23 |
Treatments |
|
| CTR20221718 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2023-08-26 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| CTR20171323 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/08/2025 |
News Article |
Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company |
|
06/17/2025 |
News Article |
TENEX.AI and WitnessAI Partner to Deliver Managed Security and Compliance Services for Enterprise AI |
|
03/12/2025 |
News Article |
VTS Announces Accelerated Investment Focus Towards an AI & Data Science-Driven Property Operations and Leasing Platform |
|
02/24/2025 |
News Article |
3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics |